GlassScriptPhysician profile
Steven B Deliduka
NPI 1598712937
$3,321.29
in general payments reported to CMS, 2019-2025
23 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $1,505 · 2021: $79.99 · 2022: $48.63 · 2023: $166 · 2024: $51.49 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.40 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,330.99 | 2020-2025 | Nemluvio |
| Genzyme Corporation | $374.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $209.66 | 2020-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $206.69 | 2019-2025 | |
| Abbvie INC. | $180.45 | 2025 | |
| Amgen INC. | $144.17 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $118.34 | 2023-2025 | Opzelura |
| Ucb, INC. | $117.17 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $106.38 | 2022-2025 | |
| Lilly USA, LLC | $86.55 | 2019-2024 | Olumiant, Taltz |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Pfizer INC. | $57.77 | 2019-2025 | |
| Medtronic, INC. | $50.97 | 2023 | V-Loc 180 |
| Organon LLC | $36.87 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $35.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $32.99 | 2019 | |
| Epi Health, LLC | $30.00 | 2022 | |
| Janssen Biotech, INC. | $29.44 | 2025 | Tremfya |
| Mission Pharmacal Company | $26.68 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.28 | 2025 | Cabtreo |
| Botanix Sb INC | $16.72 | 2025 | Sofdra |
| Journey Medical Corporation | $14.43 | 2025 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Deliduka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.